Danielle Weiss, MD presented Diabetes Care: Start the New Year Right, providing information on diabetes — from warning signs to prevention and leading-edge treatments — and strategies to enjoy good health on January 9, 2013.
In 2012, Dr. Weiss presented "A, B, C, D's of Diabetes" at the 2012 Distinguished Speaker Series, presented by Scripps Health Foundation.
On July 28, 2011, Dr. Weiss presented "Menopause: Alternatives to Hormone Replacement Therapy" at the 2011 Distinguished Speaker Series, presented by Scripps Health Foundation and community partner La Costa Glen:
Menopause is a natural part of a woman’s life - with more than 70 percent of women experiencing symptoms. Join Danielle Weiss, MD, for the latest information on alternatives to hormone replacement therapy, complimentary approaches, and non-hormonal pharmaceuticals and treatment options. Also, learn how lifestyle changes, combined with diet and supplements can benefit you by alleviate unpleasant symptoms and improve the quality of your life.
Click here for a copy of the original mailing.
For Immediate Release: June 2, 2011
Media Inquiries: JeffreyVentura, 301-796-2807, email@example.com
Consumer Inquiries: 888-INFO-FDA
FDA: Breast thermography not a substitute for mammography
Telethermographic, 'infrared' devices not approved for primary cancer screening
The U.S. Food and Drug Administration today warned women not to substitute breast thermography for mammography to screen for breast cancer.
Unlike mammography, in which an X-ray of the breast is taken, thermography produces an infrared image that shows the patterns of heat and blood flow on or near the surface of the body. Some health care providers claim thermography is superior to mammography as a screening method for breast cancer because it does not require radiation exposure or breast compression.
However, the FDA is unaware of any valid scientific evidence showing that thermography, when used alone, is effective in screening for breast cancer. To date, the FDA has not approved a thermography device (also referred to as a telethermographic device) for use as a stand-alone to screen or diagnose breast cancer. The FDA has cleared thermography devices for use only as an additional diagnostic tool for breast cancer screening and diagnosis. Therefore, FDA says, thermography devices should not be used as a stand-alone method for breast cancer screening or diagnosis.
"Mammography is still the most effective screening method for detecting breast cancer in its early, most treatable stages," said Helen Barr, M.D., director of the Division of Mammography Quality and Radiation Programs in the FDA’s Center for Devices and Radiological Health. "Women should not rely solely on thermography for the screening or diagnosis of breast cancer."
The FDA has issued warning letters to some health care providers who have been promoting the inappropriate use of breast thermography. The letters instructed the providers to cease making claims that thermography devices, when used alone, are an effective means of detecting breast cancer. Claims have, for instance, appeared on some providers’ websites.
The FDA encourages women to:
"While there is plenty of evidence that mammography is effective in breast cancer detection, there is simply no evidence that thermography can take its place," said Barr.
Click here for more information.
A Joint Statement from the American Association of Clinical Endocrinologists, the American Thyroid Association, The Endocrine Society, & the Society of Nuclear Medicine
March 18, 2011
The recent nuclear reactor accident in Japan due to the earthquake and tsunami has raised fears of radiation exposure to populations in North America from the potential plume of radioactivity crossing the Pacific Ocean. The principal radiation source of concern is radioactive iodine including iodine-131, a radioactive isotope that presents a special risk to health because iodine is concentrated in the thyroid gland and exposure of the thyroid to high levels of radioactive iodine may lead to development of thyroid nodules and thyroid cancer years later. During the Chernobyl nuclear plant accident in 1986, people in the surrounding region were exposed to radioactive iodine principally from intake of food and milk from contaminated farmlands. As demonstrated by the Chernobyl experience, pregnant women, fetuses, infants and children are at the highest risk for developing thyroid cancer whereas adults over age 20 are at negligible risk.
Radioiodine uptake by the thyroid can be blocked by taking potassium iodide (KI) pills or solution, most importantly in these sensitive populations. However, KI should not be taken in the absence of a clear risk of exposure to a potentially dangerous level of radioactive iodine because potassium iodide can cause allergic reactions, skin rashes, salivary gland inflammation, hyperthyroidism or hypothyroidism in a small percentage of people. Since radioactive iodine decays rapidly, current estimates indicate there will not be a hazardous level of radiation reaching the United States from this accident. When an exposure does warrant KI to be taken, it should be taken as directed by physicians or public health authorities until the risk for significant exposure to radioactive iodine dissipates, but probably for no more than 1-2 weeks. With radiation accidents, the greatest risk is to populations close to the radiation source. While some radiation may be detected in the United States and its territories in the Pacific as a result of this accident, current estimates indicate that radiation amounts will be little above baseline atmospheric levels and will not be harmful to the thyroid gland or general health.
We discourage individuals needlessly purchasing or hoarding of KI in the United States. Moreover, since there is not a radiation emergency in the United States or its territories, we do not support the ingestion of KI prophylaxis at this time. Our professional societies will continue to monitor potential risks to health from this accident and will issue amended advisories as warranted.
For additional information, please contact Stephanie Kutler, Director of Government and Public Affairs, at firstname.lastname@example.org.
"The Skinny on Fat" is an informative, engaging, tasteful buffet style overview on what we need to know about the one thing we love to hate.... fat! However, not all fat is bad, and indeed fat is required for good health!
Danielle Weiss, M.D. is a Stanford trained Endocrinologist specializing in metabolism, weight control, diabetes, hormonal issues and longevity. She will discuss how genetics, gender, age, hormones and lifestyle affect fat distribution, weight and metabolism.
You will learn about the different types of fat, how to have more than a fat chance of success with weight issues and the changes that occur in metabolism at different stages of life. Dr. Weiss will also provide important insights into what we can do to control our personal metabolic balance, improve our energy levels and enhance our longevity.